<DOC>
	<DOC>NCT02755220</DOC>
	<brief_summary>This study aimed to evaluate the safety and effectiveness of Cingularbio® heart valve in Aortic Valve Replacement and Mitral Valve Replacement in Chinese population</brief_summary>
	<brief_title>Cingularbio® Heart Valve Clincial Study</brief_title>
	<detailed_description>single arm, 12 month follow up, mutile center, to assess the safety and effectiveness of Cingularbio® heart valve in Aortic Valve Replacement and Mitral Valve Replacement patients</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1. age older than 60, less than 85 2. patients with the New York Heart Association ( NYHA ) score is less than IV 3. Diangosed and admintted to heart valve replacement 1. experienced heart valved implantation are contraindicated 2. the patients will experience another tricuspid valve replacement and/or coronary artery bypass graft (CABG) 3. the patients is in active endocardium</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>